Prednisolone treatment does not interfere with 2′-O-methyl phosphorothioate antisense-mediated exon skipping in duchenne muscular dystrophy

Human Gene Therapy

Volumn 23, Issue 3, 2012, Pages 262-273

  Verhaart, Ingrid E C ^a   Heemskerk, Hans ^a   Karnaoukh, Tatyana G ^b   Kolfschoten, Ingrid G M ^b   Vroon, Anne ^b   Van Ommen, Gert Jan B ^a   Van Deutekom, Judith C T ^b   Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Prosensa Therapeutics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYL PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; DYSTROPHIN; EXON 23 ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE; PREDNISOLONE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CELLS, CULTURED; DYSTROPHIN; EXONS; GENETIC THERAPY; HUMANS; MICE; MICE, INBRED MDX; MUSCLE CELLS; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; PREDNISOLONE;

MUS;

EID: 84858057818     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.127     Document Type: Article

References (75)

1. Aartsma-Rus, A., and van Ommen, G.J. (2007). Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA 13, 1609-1624. (Pubitemid 47481669)
2. Aartsma-Rus, A., Bremmer-Bout, M., Janson, A.A., et al. (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12(Suppl. 1), S71-S77. (Pubitemid 36158776)
3. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., et al. (2003). Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12, 907-914. (Pubitemid 36504033)
4. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., et al. (2004). Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet. 74, 83-92. (Pubitemid 38085240)
5. Aartsma-Rus, A., van Vliet, L., Hirschi, M., et al. (2009). Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol. Ther. 17, 548-553.
6. Acharyya, S., Villalta, S.A., Bakkar, N., et al. (2007). Interplay of IKK/NF-jB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest. 117, 889-901. (Pubitemid 46556745)
7. Alexakis, C., Partridge, T., and Bou-Gharios, G. (2007). Implication of the satellite cell in dystrophic muscle fibrosis: A self-perpetuating mechanism of collagen overproduction. Am. J. Physiol. Cell Physiol. 293, C661-C669. (Pubitemid 47235183)
8. Almon, R.R., Dubois, D.C., and Jusko, W.J. (2007). A microarray analysis of the temporal response of liver to methylprednisolone: A comparative analysis of two dosing regimens. Endocrinology 148, 2209-2225. (Pubitemid 46997037)
9. Anderson, L.V., and Davison, K. (1999). Multiplex Western blotting system for the analysis of muscular dystrophy proteins. Am. J. Pathol. 154, 1017-1022. (Pubitemid 29169736)
10. Angelini, C. (2007). The role of corticosteroids in muscular dystrophy: A critical appraisal. Muscle Nerve 36, 424-435. (Pubitemid 47512066)
11. Baltgalvis, K.A., Call, J.A., Nikas, J.B., and Lowe, D.A. (2009). Effects of prednisolone on skeletal muscle contractility in mdx mice. Muscle Nerve 40, 443-454.
12. Bates, D., and Maechler, M. (2010). lme4: Linear Mixed-Effects Models Using S4 Classes. R package version 0.999375-35.
13. Bauer, R., Straub, V., Blain, A., et al. (2009). Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur. J. Heart Fail. 11, 463-471.
14. Blake, D.J., Weir, A., Newey, S.E., and Davies, K.E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291-329. (Pubitemid 34654455)
15. Bonifati, M.D., Ruzza, G., Bonometto, P., et al. (2000). A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23, 1344-1347.
16. Bremmer-Bout, M., Aartsma-Rus, A., de Meijer, E.J., et al. (2004). Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol. Ther. 10, 232-240. (Pubitemid 39117869)
17. Cacchiarelli, D., Incitti, T., Martone, J., et al. (2011). miR-31 modulates dystrophin expression: New implications for Duchenne muscular dystrophy therapy. EMBO Rep. 12, 136-141.
18. Chamberlain, J.S., Metzger, J., Reyes, M., et al. (2007). Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21, 2195-2204. (Pubitemid 47026454)
19. Chen, Y.W., Nagaraju, K., Bakay, M., et al. (2005). Early onset of inflammation and later involvement of TGFb in Duchenne muscular dystrophy. Neurology 65, 826-834. (Pubitemid 41362124)
20. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378, 595-605.
21. Denti, M.A., Incitti, T., Sthandier, O., et al. (2008). Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum. Gene Ther. 19, 601-608. (Pubitemid 351913531)
22. Desguerre, I., Mayer, M., Leturcq, F., et al. (2009). Endomysial fibrosis in Duchenne muscular dystrophy: A marker of poor outcome associated with macrophage alternative activation. J. Neuropathol. Exp. Neurol. 68, 762-773.
23. Doran, P., Wilton, S.D., Fletcher, S., and Ohlendieck, K. (2009). Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. Proteomics 9, 671-685.
24. Emery, A.E. (2002). The muscular dystrophies. Lancet 359, 687-695. (Pubitemid 34203773)
25. Fisher, I., Abraham, D., Bouri, K., et al. (2005). Prednisoloneinduced changes in dystrophic skeletal muscle. FASEB J. 19, 834-836. (Pubitemid 40617400)
26. Gaud, A., Simon, J.M., Witzel, T., et al. (2004). Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul. Disord. 14, 365-370. (Pubitemid 38622368)
27. Goemans, N.M., Tulinius, M., van den Akker, J.T., et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513-1522.
28. Goyenvalle, A., Babbs, A., Powell, D., et al. (2010). Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol. Ther. 18, 198-205.
29. Guerron, A.D., Rawat, R., Sali, A., et al. (2010). Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne muscular dystrophy. PLoS One 5, e11220.
30. Hayden, M.S., and Ghosh, S. (2004). Signaling to NF-jB. Genes Dev. 18, 2195-2224.
31. Heemskerk, H., de Winter, C., van Kuik, P., et al. (2010). Preclinical PK and PD studies on 2¢-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther. 18, 1210-1217.
32. Heemskerk, H.A., de Winter, C.L., de Kimpe, S.J., et al. (2009). In vivo comparison of 2¢-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 11, 257-266.
33. Hoffman, E.P., Brown, R.H., Jr., and Kunkel, L.M. (1987). Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
34. Ivanova, G.D., Arzumanov, A., Abes, R., et al. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res. 36, 6418-6428.
35. Jin, Y., Murakami, N., Saito, Y., et al. (2000). Expression of MyoD and myogenin in dystrophic mice, mdx and dy, during regeneration. Acta Neuropathol. 99, 619-627. (Pubitemid 30307371)
36. Jobling, A.I., and Augusteyn, R.C. (2002). What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin. Exp. Optom. 85, 61-75.
37. Keeling, R.M., Golumbek, P.T., Streif, E.M., and Connolly, A.M. (2007). Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 35, 43-48. (Pubitemid 46052647)
38. Khan, M.A. (1993). Corticosteroid therapy in Duchenne muscular dystrophy. J. Neurol. Sci. 120, 8-14. (Pubitemid 24011141)
39. Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A singleblind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918-928.
40. Koenig, M., Monaco, A.P., and Kunkel, L.M. (1988). The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219-228.
41. Koenig, M., Beggs, A.H., Moyer, M., et al. (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. Am. J. Hum. Genet. 45, 498-506. (Pubitemid 19261437)
42. Li, D., Yue, Y., and Duan, D. (2008). Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am. J. Pathol. 172, 1332-1341. (Pubitemid 351671546)
43. Lo Cascio, V., Kanis, J.A., Beneton, M.N., et al. (1995). Acute effects of deflazacort and prednisone on rates of mineralization and bone formation. Calcif. Tissue Int. 56, 109-112.
44. Lu, Q.L., Rabinowitz, A., Chen, Y.C., et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. U.S.A. 102, 198-203. (Pubitemid 40094452)
45. Mann, C.J., Honeyman, K., McClorey, G., et al. (2002). Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med. 4, 644-654. (Pubitemid 40277188)
46. Markham, L.W., Kinnett, K., Wong, B.L., et al. (2008). Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul. Disord. 18, 365-370.
47. Marotta, M., Sarria, Y., Ruiz-Roig, C., et al. (2007). Laser microdissection-based expression analysis of key genes involved in muscle regeneration in mdx mice. Neuromuscul. Disord. 17, 707-718. (Pubitemid 47362678)
48. Mendell, J.R., Moxley, R.T., Griggs, R.C., et al. (1989). Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N. Engl. J. Med. 320, 1592-1597. (Pubitemid 19154573)
49. Merlini, L., Cicognani, A., Malaspina, E., et al. (2003). Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 27, 222-227. (Pubitemid 36169334)
50. Mezzano, V., Cabrera, D., Vial, C., and Brandan, E. (2007). Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-b and CTGF/CCN2. J. Cell Commun. Signal. 1, 205-217.
51. Monaco, A.P., Bertelson, C.J., Liechti-Gallati, S., et al. (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90-95.
52. Payne, E.T., Yasuda, N., Bourgeois, J.M., et al. (2006). Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 33, 66-77. (Pubitemid 43062988)
53. Porter, J.D., Khanna, S., Kaminski, H.J., et al. (2002). A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum. Mol. Genet. 11, 263-272. (Pubitemid 34173355)
54. R Development Core Team. (2009). R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria).
55. Ruijter, J.M., Ramakers, C., Hoogaars, W.M., et al. (2009). Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 37, e45.
56. Schakman, O., Gilson, H., Kalista, S., and Thissen, J.P. (2009). Mechanisms of muscle atrophy induced by glucocorticoids. Horm. Res. 72(Suppl. 1), 36-41.
57. Sicinski, P., Geng, Y., Ryder-Cook, A.S., et al. (1989). The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244, 1578-1580. (Pubitemid 19189735)
58. Silversides, C.K., Webb, G.D., Harris, V.A., and Biggar, D.W. (2003). Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am. J. Cardiol. 91, 769-772. (Pubitemid 36287483)
59. Spencer, M.J., and Tidball, J.G. (2001). Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul. Disord. 11, 556-564. (Pubitemid 32761799)
60. Spitali, P., Heemskerk, H., Vossen, R.H., et al. (2010). Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne muscular dystrophy. Lab. Invest. 90, 1396-1402.
61. Spurney, C.F., Knoblach, S., Pistilli, E.E., et al. (2008). Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul. Disord. 18, 371-381.
62. St-Pierre, S.J., Chakkalakal, J.V., Kolodziejczyk, S.M., et al. (2004). Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J. 18, 1937-1939. (Pubitemid 39602290)
63. Tanabe, Y., Esaki, K., and Nomura, T. (1986). Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol. 69, 91-95. (Pubitemid 16146255)
64. te Pas, M.F., de Jong, P.R., and Verburg, F.J. (2000). Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family. Mol. Biol. Rep. 27, 87-98.
65. 't Hoen, P.A., van der Wees, C.G., Aartsma-Rus, A., et al. (2006). Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. Pharmacogenomics 7, 281-297.
66. Tidball, J.G. (2005). Inflammatory processes in muscle injury and repair. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R345-R353. (Pubitemid 40129595)
67. van Putten, M., and Aartsma-Rus, A. (2011). Opportunities and challenges for the development of antisense treatment in neuromuscular disorders. Expert Opin. Biol. Ther. 11, 1025-1037.
68. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686.
69. Wu, B., Moulton, H.M., Iversen, P.L., et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophindeficient mice by a modified morpholino oligomer. Proc. Natl. Acad. Sci. U.S.A. 105, 14814-14819.
70. Wu, B., Li, Y., Morcos, P.A., et al. (2009). Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol. Ther. 17, 864-871.
71. Wu, B., Benrashid, E., Lu, P., et al. (2011). Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development. PLoS One 6, e19906.
72. Yao, W., Cheng, Z., Pham, A., et al. (2008). Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 58, 3485-3497.
73. Yin, H., Moulton, H.M., Seow, Y., et al. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet. 17, 3909-3918. (Pubitemid 352762853)
74. Yin, H., Moulton, H.M., Betts, C., et al. (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet. 18, 4405-4414.
75. Yu, R.Z., Baker, B., Chappell, A., et al. (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzymelinked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal. Biochem. 304, 19-25. (Pubitemid 34492838)